📊 SERA Key Takeaways
Is Sera Prognostics, Inc.. (SERA) a Good Investment?
SERA is a pre-revenue stage company with only $81K in annual revenue and massive operating losses of $36.5M, coupled with a cash burn rate of $26.3M in free cash flow against just $3.9M in cash reserves. The company faces severe liquidity risk with a projected cash runway of less than 2 months at current burn rates, making near-term capital infusion or dramatic operational restructuring essential for survival.
Why Buy Sera Prognostics, Inc.. Stock? SERA Key Strengths
- Zero long-term debt (0.00x Debt/Equity) reduces financial leverage risk
- Current ratio of 1.69x indicates short-term liquidity is adequate relative to current liabilities
- Stockholders' equity of $75.4M exceeds total liabilities, providing asset cushion
SERA Stock Risks: Sera Prognostics, Inc.. Investment Risks
- Critically low cash balance of $3.9M with $26.3M annual free cash flow burn creates runway of <2 months
- Revenue of only $81K is immaterial and shows zero YoY growth with no path to sustainability
- Operating losses of $36.5M indicate company is in development stage with no commercialization yet achieved
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway
- Revenue growth trajectory and path to commercial viability
- Capital raising activities and dilution to shareholders
- Reduction in operating expenses and timeline to profitability
Sera Prognostics, Inc.. (SERA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Sera Prognostics, Inc.. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
SERA Profit Margin, ROE & Profitability Analysis
SERA vs Healthcare Sector: How Sera Prognostics, Inc.. Compares
How Sera Prognostics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sera Prognostics, Inc.. Stock Overvalued? SERA Valuation Analysis 2026
Based on fundamental analysis, Sera Prognostics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sera Prognostics, Inc.. Balance Sheet: SERA Debt, Cash & Liquidity
SERA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sera Prognostics, Inc..'s revenue has remained relatively flat over the 5-year period, with a 1% decline. The most recent EPS of $-0.99 indicates the company is currently unprofitable.
SERA Revenue Growth, EPS Growth & YoY Performance
SERA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $16.0K | -$7.8M | $-0.16 |
| Q2 2025 | $17.0K | -$8.0M | $-0.16 |
| Q1 2025 | N/A | -$8.1M | $-0.20 |
| Q3 2024 | $29.0K | -$7.2M | $-0.23 |
| Q2 2024 | $24.0K | -$8.1M | $-0.25 |
| Q1 2024 | N/A | -$8.1M | $-0.25 |
| Q3 2023 | $42.0K | -$7.2M | $-0.23 |
| Q2 2023 | $78.0K | -$10.5M | $-0.34 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Sera Prognostics, Inc.. Dividends, Buybacks & Capital Allocation
SERA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sera Prognostics, Inc.. (CIK: 0001534969)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SERA
What is the AI rating for SERA?
Sera Prognostics, Inc.. (SERA) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SERA's key strengths?
Claude: Zero long-term debt (0.00x Debt/Equity) reduces financial leverage risk. Current ratio of 1.69x indicates short-term liquidity is adequate relative to current liabilities.
What are the risks of investing in SERA?
Claude: Critically low cash balance of $3.9M with $26.3M annual free cash flow burn creates runway of <2 months. Revenue of only $81K is immaterial and shows zero YoY growth with no path to sustainability.
What is SERA's revenue and growth?
Sera Prognostics, Inc.. reported revenue of $81.0K.
Does SERA pay dividends?
Sera Prognostics, Inc.. does not currently pay dividends.
Where can I find SERA SEC filings?
Official SEC filings for Sera Prognostics, Inc.. (CIK: 0001534969) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SERA's EPS?
Sera Prognostics, Inc.. has a diluted EPS of $-0.67.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SERA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Sera Prognostics, Inc.. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SERA stock overvalued or undervalued?
Valuation metrics for SERA: ROE of -42.3% (sector avg: 15%), net margin of -39,417.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SERA stock in 2026?
Our dual AI analysis gives Sera Prognostics, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SERA's free cash flow?
Sera Prognostics, Inc..'s operating cash flow is $-25.6M, with capital expenditures of $726.0K. FCF margin is -32,529.6%.
How does SERA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -39,417.3% (avg: 12%), ROE -42.3% (avg: 15%), current ratio 1.69 (avg: 2).